Dyax Corp. to Participate in the Needham Healthcare Conference Needham Healthcare Conference 2013 Business Wire BURLINGTON, Mass. -- April 29, 2013 Dyax Corp. (NASDAQ: DYAX) announced today that the Company will participate in the Needham Healthcare Conference, being held April 30-May 1, 2013, at the Westin New York Grand Central Hotel in New York City. Gustav Christensen, President and Chief Executive Officer of Dyax, will present on Tuesday, April 30 at 10:40 AM (ET). Mr. Christensen will provide a corporate update regarding the Company’s key value drivers – KALBITOR^® (ecallantide) and the angioedema portfolio, as well as the Licensing and Funded Research Program (LFRP). This presentation will be webcast live and may be accessed by visiting the Investor Relations section of the company website at www.dyax.com. The webcast will also be available on the Dyax website for a limited period of time following the conferences. About Dyax Dyax is a fully integrated biopharmaceutical company focused on the discovery, development and commercialization of novel biotherapeutics for unmet medical needs. The Company’s key value drivers are the KALBITOR®(ecallantide) business and the angioedema portfolio, as well as the Licensing and Funded Research Program (LFRP). Dyax developed KALBITOR on its own and, since February 2010, has been selling it in the United States for the treatment of acute attacks of hereditary angioedema (HAE) in patients 16 years of age and older. Outside the United States, the Company has established partnerships to obtain regulatory approval for and commercialization of KALBITOR in certain markets and is evaluating opportunities in others. The Company is currently developing products to expand its angioedema portfolio, includinga suite of diagnosticassaysto identify plasma-kallikrein-(bradykinin)-mediated (PKM) angioedemasand a therapeutic candidate, DX-2930, for the prophylactic treatment ofHAE andPKM angioedemas. KALBITOR and DX-2930 were identified using Dyax’s patented phage display technology, which rapidly selects compounds that bind with high affinity and specificity to therapeutic targets. Dyax leverages this technology broadly through the LFRP. This program has provided the Company a portfolio of product candidates being developed by its licensees, which currently includes13royalty and/or milestoneeligibleproduct candidates in various stages of clinical development, including three in Phase 3 trials. For additional information about Dyax, please visitwww.dyax.com. Foradditionalinformation about KALBITOR, including full prescribing information and boxed warning on serious hypersensitivity reactions,pleasevisitwww.KALBITOR.com. Disclaimer This press release contains forward-looking statements. Statements that are not historical facts are based onDyax'scurrent expectations, beliefs, assumptions, estimates, forecasts and projections about the industry and markets in whichDyaxcompetes. The statements contained in this release are not guarantees of future performance and involve certain risks, uncertainties and assumptions, which are difficult to predict. Therefore, actual outcomes and results may differ materially from what is expressed in such forward-looking statements. Important factors which may affect future performance include the risks that: DX-2930 may not show sufficient therapeutic effect or an acceptable safety profile in clinical trials or could take longer to gain regulatory approval thanDyaxexpects or may never gain approval; others may develop products superior to KALBITOR or DX-2930; KALBITOR and/or DX-2930 may not gain market acceptance;Dyaxis dependent on the expertise, effort, priorities and contractual obligations of third parties in the manufacture, marketing, sales and distribution of KALBITOR and DX-2930; and other risk factors described or referred to in Item 1A, "Risk Factors" inDyax'smost recent Annual Report on Form 10-K and other periodic reports filed with theSecurities and Exchange Commission.Dyaxcautions investors not to place undue reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this release, andDyaxundertakes no obligations to update or revise these statements, except as may be required by law. Dyax, theDyaxlogo and KALBITOR are registered marks ofDyax Corp. Contact: Dyax Corp. Jennifer Robinson, 617-250-5741 Associate Director, Investor Relations and Corporate Communications email@example.com
Dyax Corp. to Participate in the Needham Healthcare Conference
Press spacebar to pause and continue. Press esc to stop.